表紙
市場調査レポート

ボツリヌス神経毒素:製品、パイプライン、技術およびステークホルダーの比較産業分析

Botulinum Neurotoxins: A Comparative Industry Analysis of Products, Pipelines, Technologies and Stakeholders

発行 La Merie Publishing 商品コード 308429
出版日 ページ情報 英文 169 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ボツリヌス神経毒素:製品、パイプライン、技術およびステークホルダーの比較産業分析 Botulinum Neurotoxins: A Comparative Industry Analysis of Products, Pipelines, Technologies and Stakeholders
出版日: 2014年07月18日 ページ情報: 英文 169 Pages
概要

ボツリヌス神経毒素製品市場は、新たな医学的適応の開発により、そして見た目がもてはやされる高齢化社会で多くの美容的処置が行われたことから、この数年間で大幅に成長しています。商業的なボツリヌス毒素市場はたった1社によって独占されていますが、既存の競合企業、新しい企業および技術はバイオスーペリアおよびバイオシミラーにとっての基礎を築いています。バイオシミラーボツリヌス毒素は第1世代製品の価格に圧力をかけ、革新のみが高価な価格を正当化するようになるでしょう。

当レポートでは、規制の厳しい市場および規制の緩い市場におけるボツリヌス神経毒素(BoNT)の既存製品ポートフォリオについて分析し、商業的情報、売上・市場シェアの測定およびライフサイクル管理の測定を提供しており、バイオシミラーおよびバイオスーペリアボツリヌス神経毒素といった、開発中のボツリヌス神経毒素製品候補薬の新たな波なども取り上げています。

第1章 エグゼクティブサマリー

第2章 概要

  • 歴史的背景
  • ボツリヌス神経毒素(BoNT)の構造・機能

第3章 規制の厳しい市場で入手可能なボツリヌス神経毒素製品

  • 規制の厳しい市場におけるBoNTの承認適用
  • 規制の厳しい市場におけるBoNT製品の主な製品特徴
  • 規制の厳しい市場におけるボツリヌス毒素製品の価格
  • ボツリヌス毒素製品の売上と市場シェア
  • 商用BoNT製品の成功要因
  • 製品におけるパイプライン
  • EU/米国におけるBoNTの製品ライフサイクル管理
  • EU/米国において中止されたBoNTの開発

第4章 規制の緩い市場におけるBoNT

第5章 バイオシミラーボツリヌス神経毒素

第6章 バイオスーペリア、次世代ボツリヌス神経毒素

  • すぐに可能な(Ready-to-use)液剤のBoNT注射剤
  • 局所製剤におけるBoNTの経皮デリバリー
  • 人工・修飾ボツリヌス毒素

第7章 ボツリヌス神経毒素市場のステークホルダーおよびイネーブリング技術

  • 西洋市場の既存企業
  • 既存BoNT市場企業の課題
  • 次世代BoNT向けのイネーブリング技術

第8章 ボツリヌス神経毒素の企業プロファイル

  • Allergan
  • Alphaeon
  • Anterios
  • CROMA Pharma
  • Daewoong Pharmaceutical Co
  • エーザイ
  • Escape Therapeutics
  • Galderma
  • Hugel
  • Ipsen
  • Johnson & Johnson (Mentor)
  • Lanzhou Institute of Biological Producs (LIBP)
  • Lipella Pharmaceuticals
  • Malvern Cosmeceutics
  • Medy-Tox
  • Merz Pharmaceuticals
  • OBI Pharma
  • Revance Therapeutics
  • Transdermal Corp
  • US WorldMeds

第9章 参考資料

第10章 競合薬の分析図

  • オナボツリヌス毒素A(OnabotulinumtoxinA )のパイプライン
  • AbobotulinumtoxinAのパイプライン
  • IncobotulinumtoxinAのパイプライン
  • RimabotulinumtoxinBのパイプライン
  • 規制の厳しい市場における新規・バイオシミラーボツリヌス神経毒素タイプA(BoNT/A)
  • 規制の緩い市場におけるボツリヌス神経毒素タイプA(BoNT/A)
  • ボツリヌス神経毒素タイプA(BoNT/A)の液剤
  • ボツリヌス神経毒素タイプA(BoNT/A)局所製剤
  • 修飾/人口ボツリヌス神経毒素

企業のボツリヌス菌製品ポートフォリオおよびR&Dパイプライン

図表リスト

目次
Product Code: LMFR0013

This business report from July 2014 is based on the identification, description and assessment of all relevant stakeholders in the field of botulinum neurotoxins. The report analyzes the existing product portfolios in regulated and less regulated markets, commercial information, and measures to maintain sales and market shares by upside indications and life cycle management measures. The report addresses the new wave of botulinum neurotoxin product candidates in development, such as biosimilars and biosuperior botulinum neurotoxins.

Special emphasis is put in the report on improvements by pharmaceutical technologies, such as liquid protein formulations and transdermal drug delivery technologies. The significance of recombinant DNA technology is discussed regarding botulinum neurotoxin engineering, modification and manufacturing. Chances and challenges for the stakeholders in the botulinum neurotoxin market are evaluated.

The market for botulinum neurotoxin products has significantly grown over the last years, due to new medical indications developed and due to more cosmetic procedures performed with botulinum neurotoxins in ageing societies in which physical appearance is highly valued. Although the botulinum neurotoxin market commercially is dominated by only one company, existing competitors, new players and technologies are setting the ground for biosuperiors as well as for biosimilars. As biosimilar botulinum toxins will put the price of first generation products under pressure, only innovation can justify higher prices.

Benefits from the report:

  • Identify established and emerging players in the field;
  • Find out which enabling technologies are attractive for the next generation;
  • Understanding the driving forces for the future of the botulinum neurotoxin market;
  • Learn the key success factors in marketing new botulinum neurotoxin products;
  • Recognize the challenges acting on established stakeholders;
  • Learn which technologies and product candidates are attractive for partnering;

Table of Contents

1. Executive Summary

2. Overview

  • 2.1 Historical Background
  • 2.2 Structure and Function of Botulinum Neurotoxins (BoNT)

3. Botulinum Neurotoxin Products Available in Regulated Markets

  • 3.1 Approved indications of BoNTs in regulated markets
  • 3.2 Key product features of BoNT products in regulated markets
  • 3.3 Pricing of botulinum toxin products in regulated markets
  • 3.4 Botulinum toxin product sales and market shares
  • 3.5 Commercial BoNT product success factors
  • 3.6 Pipeline in a product
  • 3.7 Product life cycle management of BoNT in EU/US
  • 3.8 Discontinued development of BoNT in EU/US

4. BoNTs in Less Regulated Markets

5. Biosimilar Botulinum Neurotoxin

6. Biosuperior, Next Generation Botulinum Neurotoxins

  • 6.1 Ready-to-use injectable BoNT in liquid formulation
  • 6.2 Transdermal delivery of BoNT in topical formulation
  • 6.3 Engineered and modified botulinum toxins

7. Botulinum Neurotoxin Market Stakeholders and Enabling Technologies

  • 7.1 The established Western market players
  • 7.2 Challenges for established BoNT market players
  • 7.3 Enabling technologies for next generation BoNT

8. Botulinum Neurotoxin Company Profiles

  • Allergan
  • Alphaeon
  • Anterios
  • CROMA Pharma
  • Daewoong Pharmaceutical Co
  • Eisai
  • Escape Therapeutics
  • Galderma
  • Hugel
  • Ipsen
  • Johnson & Johnson (Mentor)
  • Lanzhou Institute of Biological Producs (LIBP)
  • Lipella Pharmaceuticals
  • Malvern Cosmeceutics
  • Medy-Tox
  • Merz Pharmaceuticals
  • OBI Pharma
  • Revance Therapeutics
  • Transdermal Corp
  • US WorldMeds

9. References

10. Competitor Analysis Tables

  • OnabotulinumtoxinA Pipeline
  • AbobotulinumtoxinA Pipeline
  • IncobotulinumtoxinA Pipeline
  • RimabotulinumtoxinB Pipeline
  • Novel and Biosimilar Botulinum Neurotoxin type A (BoNT/A) in Regulated Markets
  • Botulinum Neurotoxin type A (BoNT/A) in Less Regulated Markets
  • Liquid Formulation of Botulinum Neurotoxin type A (BoNT/A)
  • Topical Formulation of Botulinum Neurotoxin type A (BoNT/A)
  • Modified/Engineered Botulinum Neurotoxin

Corporate Botulinum Toxin Product Portfolios and R&D Pipelines:

  • Allergan
  • Alphaeon
  • Anterios
  • CROMA Pharma
  • Daewoong Pharmaceutical Co
  • Eisai
  • Escape Therapeutics
  • Galderma
  • Hugel
  • Ipsen
  • Johnson & Johnson (Mentor)
  • Lanzhou Institute of Biological Producs (LIBP)
  • Lipella Pharmaceuticals
  • Malvern Cosmeceutics
  • Medy-Tox
  • Merz Pharmaceuticals
  • OBI Pharma
  • Revance Therapeutics
  • Transdermal Corp
  • US WorldMeds

List of Tables

  • Table 1 Comparison of Approved Indications of Botulinum Toxins in EU/US
  • Table 2 Comparison of Pharmaceutical Product Features of BoNTs in EU/US
  • Table 3 Pricing of Botulinum Toxin Products in EU/US
  • Table 4 Worldwide Sales of Botox and Dysport
  • Table 5 Scientific Evidence from Peer-reviewed Literature about Marketed BoNTs in EU/US
  • Table 6 Pipeline in a Product: Comparison of Follow-up Indications of BoNTs in EU/ US
  • Table 7 Comparison of Product Features of non-US/EU-GMP Compliant BoNTs
  • Table 8 Comparison of Product Features of Potential Biosimilar BoNTs for EU/US Markets
  • Table 9 Comparison of Product Features of Liquid BoNTs for EU/US Markets
  • Table 10 Comparison of Product Features of Topical Botulinum Toxins
  • Table 11 Overview of Engineered and Modified Botulinum Toxin R&D Projects
  • Table 12 Present and Future Key Success Factors for Established BoNT Players in EU/US
  • Table 13 Global Botox/Vistabel Sales and US Approval of New Indications
  • Table 14 Key Product Features of Botox
  • Table 15 Medical and cosmetic indications of Botox under development
  • Table 16 Key Product Features of Senrebotase
  • Table 17 Postherpetic Neuralgia Study Results of Senrebotase
  • Table 18 Overview on clinical studies conducted with Anterios' topical botulinum toxin typ A cream
  • Table 19 Key Product Features of ANT-1207
  • Table 20 Key Product Features of AI-09
  • Table 21 Key Product Features of Nabota
  • Table 22 Overview on Commercialization of Nabota
  • Table 23 NeuroBloc Pruduct Characteristics
  • Table 24 Azzalure Pruduct Characteristics
  • Table 25 Key Product Features of Botulax
  • Table 26 Overview on Commercialization of Botulax
  • Table 27 Dysport Pruduct Characteristics
  • Table 28 Dysport sales
  • Table 29 Key Product Features of PurTox
  • Table 30 Key Product Features of BTXA
  • Table 31 Key Product Features of Meditoxin
  • Table 32 Formulation Patent Applications by Medytox
  • Table 33 Xeomin Pruduct Characteristics
  • Table 34 IncobotulinumtoxinA Sales
  • Table 35 Financing history of Revance Therapeutics
  • Table 36 Key Product Features of RT001
  • Table 37 Key Product Features of RT002
  • Table 38 Key Product Features of CosmeTox / Topical BoNTA
  • Table 39 Key Product Features of A2NTX
  • Table 40 Myobloc Pruduct Characteristics

Companies mentioned in the report

  • Allergan
  • Alphaeon
  • Anterios
  • Bago
  • Bon-Song
  • Chong Kun Dang
  • CROMA Pharma
  • Daewoong Pharmaceutical Co
  • Eisai
  • EpiVax
  • Escape Therapeutics
  • Galderma
  • GlaxoSmithKline
  • Hugel
  • Ipsen
  • Johnson & Johnson
  • Lanzhou Institute of Biological Producs (LIBP)
  • Lipella Pharmaceuticals
  • List Biological Laboratories
  • Malvern Cosmeceutics
  • Medicis
  • Medy-Tox
  • Mentor Corp.
  • Merz Pharmaceuticals
  • Metabiologics
  • Nestle
  • OBI Pharma
  • Oxbridge Pharma
  • PharmaVital
  • Revance Therapeutics
  • Syntaxin
  • TKJ
  • Transdermal Corp
  • University of Tokushima
  • US WorldMeds
  • Valeant Pharmaceuticals
Back to Top